The angiotensin-converting enzyme (ACE) gene (ACE) is one of the most studied candidate genes related to essential hypertension (EH) and left ventricular hypertrophy (LVH).
Introduction
Essential hypertension (EH) is a common disorder in which multiple genetic factors account for 40% of blood pressure variability (1). Because the renin-angiotensin system (RAS) plays an important role in the regulation of blood pressure as well as water and sodium balance (2) , genetic variants in the RAS have been examined as candidates for causing hypertension (3) . The key enzyme of this system, angiotensin-converting enzyme (ACE), catalyzes the production of angiotensin II, which acts as a strong vasoobliterant and stimulates the secretion of aldosterone (4) . Published studies have shown that the insertion/deletion (I/D) polymorphism in intron 16 of the ACE gene (ACE) accounts for approximately half the variance in ACE plasma levels (5) . Consequently, ACE has been postulated as a candidate gene for the development of EH. Zee et al. (6) first showed that the DD genotype is associated with increased risk of EH in a case-control study in Caucasians, but subsequent studies have yielded conflicting results (7) .
The physiological function of the I/D polymorphism has not yet been clarified. It is likely that this polymorphism is in strong linkage disequilibrium with another functional mutation within the gene (8) . Recently, a genome-scan analysis by the Framingham Heart Study group found strong evidence of a quantitative-trait locus (QTL) on chromosome 17, which was close to the ACE and was linked to blood pressure (9) . Among the 13 polymorphisms of the ACE that have recently been reported, rs4343 synonymous coding polymorphism (2350 G/A) has been shown to exert the most significant effect on plasma ACE concentrations (10) .
Based on these findings, we carried out a case-control study of the ACE 2350 G/A polymorphism to examine its putative association with EH in a Chinese Han population. We also assessed the association of this polymorphism with hypertensive left ventricular hypertrophy (LVH).
Methods

Study Population
A total of 246 patients with EH (including 178 untreated hypertensive subjects) were eligible for this study. The subjects were enrolled at the First Affiliated Hospital of Soochow University (Suzhou, P.R. China). Hypertension was diagnosed if blood pressure measurements on at least three separate occasions were ≥ 140 mmHg for systolic and/or ≥ 90 mmHg for diastolic blood pressure, or when the participant was taking antihypertensive agents. Subjects with secondary hypertension, diabetes mellitus, valvular disease, or apparent ischemic heart disease were excluded. The controls were 194 age-, gender-, and body mass index (BMI)-matched healthy individuals. The controls had no history of hypertension or diabetes mellitus. Normotension was defined as systolic blood pressure (SBP) < 140 mmHg, diastolic blood pressure (DBP) < 90 mmHg, and lack of current antihypertensive drug treatment. We also excluded from the control group those subjects whose first-degree relatives had hypertension. All study participants were unrelated Han nationality residents of Suzhou (south of P.R. China). No participants included in the sample admitted to any regular alcohol intake. There was also no history of cigarette smoking among these subjects. The study was approved by the Medical Ethics Committee of Soochow University, and written informed consent was obtained from all participants.
Evaluation of LVH
Two-dimensional-controlled M-mode echocardiograms were recorded with each untreated hypertensive subject in the partial left decubitus position after a resting period of at least 10 min. According to the criteria set by the American Society of Echocardiography (11), the following parameters relative to the left ventricle were obtained in a blinded fashion, each as an average of at least 3 measurements: 1) left ventricular enddiastolic diameter (LVEDD), 2) left ventricular end-systolic diameter (LVESD), 3) left ventricular diastolic posterior wall thickness (LVDPWT), 4) interventricular septum thickness (IST), and ejection fraction (EF) measured according to the Teicholz method. Left ventricular mass was determined by the Devereux and Reicheck formula (12) and the obtained value was divided by the body surface area in order to calculate the left ventricular mass index (LVMI). LVH was diagnosed if the LVMI exceeded 100 g/m 2 in women and 131 g/m 2 in men (13) . The relative wall thickness (RWT) was measured by using the standardized formula (14): 2 × LVD-PWT/LVEDD.
Determination of Genotype
Genomic DNA was extracted from peripheral blood leukocytes by the salting-out method (15) , with minimal modifications. The 2350 G/A genotype in the ACE was determined by polymerase chain reaction (PCR) and restriction fragment Table 1 .
length polymorphism (RFLP) as described previously (10), with the following modification: a mismatch guanine was introduced at the 3′ end of the primer sequence, resulting in the amplification of a BstU1 restriction site. A 122-bp PCR amplification product was generated from genomic DNA using the following primers: 5′-CTGACGAATGTGATGGC CGC-3′ (sense) and 5′-TTGATGAGTTCCACGTATTTCG-3′ (antisense). PCR reactions were carried out with 200 ng of genomic DNA in a total volume of 50 μl, containing 1.5 mmol/l Mg 2+ , 5 μl 10× buffer, 0.02 μmol of each of the four dNTPs, 20 pmol of each of the primers, and 1.5 U of DNA polymerase. Thermal processing was initiated at 95°C for 5 min, and then 35 cycles were carried out at 94°C for 30s, 58°C for 30 s, and 72°C for 30 s. This series of cycles was followed by a final extension at 72°C for 10 min. All PCR reactions were carried out in a Perkin-Elmer 9600 thermal cycler (Perkin-Elmer, Foster City, USA). Twenty microliters of the PCR product were digested using 5 U of BstU1 restriction endonuclease (New England Biolabs, Beverly, USA) in 25-μl volumes at 37°C overnight. Digestion with BstU1 yields 100-and 22-bp fragments when A is at position 2350. The digestion products were then separated by electrophoresis on 4% agarose gel, and were stained with ethidium bromide.
Statistical Analysis
All continuous variables are expressed as the mean±SD. Student's t-test and analysis of variance (ANOVA) followed by the Newman-Keuls test were used to compare continuous variables from two groups and multiple groups, respectively. Genotypes and allele frequencies were obtained by direct count. Differences in the distribution of alleles and genotypes between the groups, and deviations from the Hardy-Weinberg equilibrium were assessed by χ 2 test. A logistic regression analysis was performed to assess the influence of several factors involved in the association between the ACE 2350G/A polymorphism genotype distribution and LVH. All significant tests were two-tailed and were considered statistically significant at p< 0.05. SAS software (Version 8, SAS Institute, Cary, USA) was used for all statistical analyses.
Results
The clinical characteristics of all participants enrolled in the study are depicted in Table 1 . There were no significant differences in gender, age, or BMI between the hypertensive and control groups. In this study, 178 untreated hypertensives were divided into LVH(+) and LVH(−) groups according to the echocardiographic diagnosis. The two groups had no significant differences in gender, age, or BMI, or in SBP or DBP (Table 2) . Table 3 summarizes the distributions of ACE 2350 G/A genotypes and allele frequencies for all groups. The genotype distribution among the subjects was in Hardy-Weinberg equilibrium in both the control group (χ 2 = 0.80, p= 0.37) and the EH group (χ 2 = 0.75, p= 0.39). All subgroups in the EH group also were within Hardy-Weinberg proportions (p> 0.05). The distribution of the ACE 2350 G/A genotypes (GG, GA, and AA) was 34.02%, 45.88%, and 20.10% for the controls, and 28.46%, 47.15%, and 24.39% for all EH subjects, respectively. The derived allele frequencies for the G and A alleles were 56.96% and 43.04% in the control subjects, and 52.03% and 47.97% in the EH subjects respectively. There were no significant differences in either genotype frequency distribution (p= 0.3659) or allele frequency distribution (p= 0.1453) between these two groups, which suggested that the 2350 G/ A polymorphism of the ACE was not significantly associated with EH. On the other hand, the distribution of genotype frequency in the LVH(+) group showed a significant difference when compared to that of controls (p= 0.0075), namely, the frequency of the A allele in the LVH(+) group was significantly higher than that of subjects in the control group (58.09% vs. 43.04%, p= 0.0025). Moreover, there were significant differences in both genotype distribution (χ 2 = 9.9238, p= 0.0070) and allele frequency distribution (χ 2 = 8.4184, p= 0.0037) between the LVH(+) group and the LVH(−) group. The relative risk of LVH in GA+AA patients compared with that of GG patients was 3.31 (95% confidence interval [CI]: 1.43 to 7.68). In addition, in a stepwise logistic regression model using LVH as the dependent variable and age, BMI, blood pressure, and ACE 2350 G/A polymorphism genotype as independent variables, the presence of the A allele (GA +AA genotypes) was the only variable independently associated with LVH (p= 0.0035).
The effects of the different genotypes on blood pressure are shown in Table 4 . There were no significant differences in SBP or DBP among the three genotypes in the control and untreated EH groups. The effects of different genotypes on echocardiographic parameters in untreated hypertensives are shown in Table 5 . Because there were no differences in echocardiographic parameters between GA and AA genotypes, the carriers of the A allele (GA+AA) were pooled into one group. EH patients with the GA+AA genotype had greater left ventricular dimensions and thickness than did patients with the GG genotype. Values of LVEDD (49.52±4.14 vs. 45.34±3.78 mm, p= 0.0000), LVDPWT (10.39±1.03 vs. 9.98±0.86 mm, p= 0.0135), and LVMI (144.86±10.26 vs. 138.75±8.45 g/m 2 , p= 0.002) were significantly higher in GA+AA patients compared with those of GG patients.
Discussion
During the past decade, there has been growing interest in ACE I/D polymorphism as a potential risk factor for EH, in particular after Rigat et al. (16) reported that more than half of the variance in plasma ACE levels is under the influence of the I/D polymorphism. Zee et al. (6) first showed that the DD genotype is associated with increased risk of EH in a casecontrol study of Caucasians. That report was then followed by a number of studies that either supported (17) (18) (19) (20) or failed to confirm the original hypothesis (21, 22) .
The ACE I/D polymorphic locus, identified in a non-coding sequence, is more likely to serve as a genetic marker due to its linkage disequilibrium (LD) with a nearby putative diseasecausing locus (8) . Zhu et al. (10) genotyped 13 polymorphisms in the ACE by performing linkage and association analyses, and they found that the 2350 G/A polymorphism in exon 17 had the most significant effect on the plasma ACE concentration, accounting for 19% of the total variance in ACE plasma levels. After adjustment for the effect of the ACE 2350 G/A polymorphism, the I/D polymorphism was no longer associated with ACE levels. Their results implied that I/D polymorphism is in LD with 2350 G/A polymorphism and is therefore unlikely to be a functional mutation.
The association between EH as well as hypertensive LVH and the ACE 2350 G/A polymorphism has not been studied in the Chinese population. In the present study, we examined the association of the ACE 2350 G/A polymorphism in Chinese Han patients suffering from EH.
In this study, no significant difference was observed in either genotype frequency distribution (p= 0.3659) or in allele frequency distribution (p= 0.1453) between the control and EH groups, suggesting that the 2350 G/A polymorphism of the ACE is not significantly associated with EH. We also found no significant differences in SBP or DBP among the three genotypes of controls and untreated EH subjects. This result was not in agreement with the results of the only reported study carried out in an Emirati sample (23) , which showed that the ACE GG 2350 genotype was positively associated (odds ratio [OR]=1.06-3.07, p= 0.02) with EH. The discrepancy is likely due to the heterogeneity of subject backgrounds. In addition, the relatively small sample studied in our report (194 controls and 246 EH patients) and in the previous study (136 controls and 118 EH patients) is also likely to be responsible for the discrepancy. It is of interest that the data obtained from the Emirati population also showed no significant differences in SBP or DBP among the three genotypes. Because EH is a complex trait that is influenced by many factors, further studies will still need to be carried out using larger samples and on groups with different environmental exposure status.
LVH is a major independent risk factor for morbidity and mortality due to cardiovascular disease (24) . Although blood pressure, stroke volume, and decreases in contractile efficiency are important determinants of LVH (25), the patho- genic mechanism of LVH may be multifactorial, involving both hemodynamic and nonhemodynamic factors, such as the sympathetic nervous system and the RAS (26) . Neuroendocrine factors such as angiotensin II and bradykinin have also been implicated in the modulation of cardiac growth (27) . Experimental studies suggest that angiotensin II may stimulate cardiac protein synthesis, whereas bradykinin may have an anti-proliferative effect (28) . ACE is a key enzyme in the production of angiotensin II as well as in the degradation of bradykinin (4) . The experimental data reported thus far suggests that ACE plays a role in the pathogenesis of LVH. Moreover, several studies have investigated the influence of genetic background on the variability in left ventricular mass in humans, and the heritability of this trait has been estimated to be between 30% and 70% in different populations (29) . Saeed et al. (30) first showed that the ACE 2350 G/A polymorphism is associated with increased risk of LVH in a nonhypertensive Emirati population. However, there is still little information about other ethnic groups.
In the present study, significant differences of ACE 2350 G/ A genotypes and allele frequencies were found between patients with LVH and without this complication in untreated hypertensives. We further demonstrated that EH patients with the GA +AA genotype had greater left ventricular dimensions and thickness than did patients with the GG genotype. The A allele was associated with LVH. A logistic regression analysis showed that the association of the A allele with LVH was independent of age, blood pressure, and BMI. Our data support an earlier report of the association between ACE 2350 G/ A polymorphism and LVH (30) . Table 6 shows a comparison of 2350 G/A genotype and allele frequencies between Chinese and Emirati populations (30) . There was no significant difference among the healthy controls, either in terms of genotype frequency distribution (p= 0.0547) or allele frequency distribution (p= 0.2080) between the two populations. However, the observed 2350 G/ A genotypes in the Emirati controls were not in agreement with the predicted Hardy-Weinberg equilibrium values. The frequency of the A allele in Chinese healthy controls was significantly higher (p< 0.05) than that of a Pakistani sample (0.298) (31), but lower (p< 0.05) than that of a Caucasian sample (0.513-0.542) (32) (33) reported a synonymous mutation in the human dopamine receptor D2 (DRD2); rather than being "silent," it altered the predicted mRNA folding, and led to a decrease in mRNA stability and translation, and dramatically changed dopamine-induced up-regulation of DRD2 expression. The data obtained in that study were suggestive of a possible role played by certain synonymous mutations on functional effects. However, the ACE 2350G/A polymorphism may very well not be the actual functional mutation in this context. Instead, it might be located near another functional mutation, as yet undiscovered, in ACE or any other gene that could be in LD with it in this region of chromosome 17. In fact, in our study, the frequency of the A allele of ACE 2350G/A in patients with LVH was significantly higher than in the controls, while a previous study of a Nigerian sample showed the G allele of the ACE 2350G/A polymorphism is most significantly associated with increased plasma ACE levels (10) . This discrepancy between genotype and phenotype among different populations was also reported by Zhu et al. (10) . In their study, the alleles of different SNPs in the ACE responsible for the ACE concentration in a Nigerian sample had the opposite effects in a European population. These discrepant findings suggest that all of these polymorphisms are not functional variants, but instead are in strong LD with a functional variant. Thus, the mechanisms of the association of the ACE 2350G/A polymorphism with LVH and ACE concentration in the Chinese population should be examined in future studies.
In conclusion, our data support that ACE 2350 G/A polymorphism is associated with LVH but not EH, and the A allele is an independent risk for LVH in Chinese Han EH patients. Given the inherent limitations of case-control studies and the complex nature of genetic susceptibility for chronic degenerative diseases, further studies will still need to be conducted in individual ethnic groups to verify the relevance of this polymorphism to the development of disease. 
